Wo2015/134998 berotralstat?

WO2015/134998 – “Berotralstat” (Kallikrein Inhibitor)
(Published 2015, assigned to Pfizer Inc.)

1. What is the Patent about?

• Type: International Patent Application (WO)
• Title (as in the filing): “Kallikrein inhibitors for the prevention of hereditary angioedema attacks”
• Key Claims:
  • The invention covers the use of berotralstat (a small‑molecule, selective plasma kallikrein inhibitor) for the prophylactic treatment of hereditary angioedema (HAE).
  • It also claims specific dosage‑form compositions (e.g., oral tablets, capsules) and therapeutic regimens (daily dosing, dosing intervals).
  • The patent discusses formulation excipients that improve stability, bioavailability, and patient acceptability.
  • It includes pharmacokinetic profiling and pharmacodynamic endpoints for establishing efficacy.

Bottom line: WO2015/134998 protects the use of berotralstat as a preventive HAE therapy, the specific chemical formulation, and the recommended dosing schedule.

2. What is Berotralstat?